BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2510141)

  • 1. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity.
    Haj-Yehia A; Bialer M
    Pharm Res; 1989 Aug; 6(8):683-9. PubMed ID: 2510141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity.
    Haj-Yehia A; Bialer M
    J Pharm Sci; 1990 Aug; 79(8):719-24. PubMed ID: 2231336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.
    Bialer M; Hadad S; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Yagen B
    Pharm Res; 1996 Feb; 13(2):284-9. PubMed ID: 8932450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
    Blotnik S; Bergman F; Bialer M
    Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of the structural requirements for forming "stable" analogues of valpromide.
    Haj-Yehia A; Hadad S; Bialer M
    Pharm Res; 1992 Aug; 9(8):1058-63. PubMed ID: 1409378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.
    Levi M; Yagen B; Bialer M
    Pharm Res; 1997 Feb; 14(2):213-7. PubMed ID: 9090712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats.
    Mareš P; Kubová H; Hen N; Yagen B; Bialer M
    Epilepsy Res; 2013 Sep; 106(1-2):64-73. PubMed ID: 23815889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs.
    Haj-Yehia A; Bialer M
    J Pharm Sci; 1988 Oct; 77(10):831-4. PubMed ID: 3148708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.
    Winkler I; Blotnik S; Shimshoni J; Yagen B; Devor M; Bialer M
    Br J Pharmacol; 2005 Sep; 146(2):198-208. PubMed ID: 15997234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--Amide derivatives of valproic acid.
    Mawasi H; Shekh-Ahmad T; Finnell RH; Wlodarczyk BJ; Bialer M
    Epilepsy Behav; 2015 May; 46():72-8. PubMed ID: 25863940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid.
    Spiegelstein O; Yagen B; Levy RH; Finnell RH; Bennett GD; Roeder M; Schurig V; Bialer M
    Pharm Res; 1999 Oct; 16(10):1582-8. PubMed ID: 10554101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.
    Bialer M
    J Control Release; 1999 Nov; 62(1-2):187-92. PubMed ID: 10518650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a central nervous system--active chiral valproylamide.
    Wasserman M; Yagen B; Blotnik S; Papo N; Bialer M
    Ther Drug Monit; 2001 Aug; 23(4):414-20. PubMed ID: 11477326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.
    Isoherranen N; White HS; Klein BD; Roeder M; Woodhead JH; Schurig V; Yagen B; Bialer M
    Pharm Res; 2003 Aug; 20(8):1293-301. PubMed ID: 12948028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid.
    Hadad S; Vree TB; van der Kleijn E; Bialer M
    Biopharm Drug Dispos; 1993 Jan; 14(1):51-9. PubMed ID: 8427944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid.
    Radatz M; Ehlers K; Yagen B; Bialer M; Nau H
    Epilepsy Res; 1998 Mar; 30(1):41-8. PubMed ID: 9551843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid.
    Bialer M; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Shirvan M
    Biopharm Drug Dispos; 1996 Oct; 17(7):565-75. PubMed ID: 8894115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.
    Bialer M; Haj-Yehia A; Barzaghi N; Pisani F; Perucca E
    Eur J Clin Pharmacol; 1990; 38(3):289-91. PubMed ID: 2111246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we develop improved derivatives of valproic acid?
    Bialer M; Haj-Yehia A; Badir K; Hadad S
    Pharm World Sci; 1994 Feb; 16(1):2-6. PubMed ID: 8156045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential.
    Shekh-Ahmad T; Hen N; Yagen B; McDonough JH; Finnell RH; Wlodarczyk BJ; Bialer M
    Epilepsia; 2014 Feb; 55(2):353-61. PubMed ID: 24313671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.